<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>LAT1 &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/lat1/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 16 Oct 2026 19:39:11 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>LAT1 &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Two-in-one boron compound fights tumors and powers neutron capture therapy</title>
		<link>https://bioengineer.org/two-in-one-boron-compound-fights-tumors-and-powers-neutron-capture-therapy/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 16 Oct 2026 19:39:11 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[BNCT]]></category>
		<category><![CDATA[boron delivery agents]]></category>
		<category><![CDATA[boron neutron capture therapy]]></category>
		<category><![CDATA[BPA]]></category>
		<category><![CDATA[carborane]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[erlotinib]]></category>
		<category><![CDATA[LAT1]]></category>
		<category><![CDATA[melanoma]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<category><![CDATA[quinazoline]]></category>
		<category><![CDATA[targeted cancer therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=423485</guid>

					<description><![CDATA[A carborane-quinazoline hybrid derived from erlotinib delivered boron to tumor cells far more efficiently than BPA and delayed tumor growth in melanoma and lung cancer models, supporting its development as a bifunctional agent for boron neutron capture therapy.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">423485</post-id>	</item>
	</channel>
</rss>
